drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting the EGFRvIII mutant epitope; administered locally to the CNS via an Ommaya reservoir to eliminate EGFRvIII-positive glioblastoma cells through HLA-independent T-cell activation, cytokine release, and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that specifically binds the tumor-specific EGFRvIII epitope on glioblastoma cells, enabling HLA-independent recognition. CAR signaling activates the T cells (via CD3ΞΆ and costimulatory domains), inducing cytokine release, proliferation, and targeted cytotoxic killing of EGFRvIII-positive tumor cells; administered locally to the CNS via an Ommaya reservoir.
drug_name
EGFRvIII CAR-T (DCTY0801)
nct_id_drug_ref
NCT05802693